Loading clinical trials...
Loading clinical trials...
A Registered Randomized, Double-Blind, Placebo-Controlled (2:1), Multi-Centered Clinical Trial of Anlotinib as a Treatment for Advanced Non-Small Cell Lung Cancer
Conditions
Interventions
Anlotinib
Placebo
Locations
40
China
Beijing Friendship Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Capital Medical University, Beijing Chest Hospital
Beijing, Beijing Municipality, China
Chinese Academy of Medical Sciences Cancer Hospital
Beijing, Beijing Municipality, China
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Chongqing Cancer Hospital
Chongqing, Chongqing Municipality, China
Xinqiao Hospital
Chongqing, Chongqing Municipality, China
Start Date
February 26, 2015
Primary Completion Date
January 5, 2017
Completion Date
January 6, 2017
Last Updated
September 18, 2017
NCT07190248
NCT06305754
NCT07100080
NCT07195695
NCT06357533
NCT06731413
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions